How should I manage a patient who is already receiving phenytoin but is experiencing breakthrough seizures?

Management of Breakthrough Seizures in Patients Already on Phenytoin

For a patient on phenytoin who is experiencing breakthrough seizures, immediately check the phenytoin level and add a second-line agent—valproate (20-30 mg/kg IV at 40 mg/min) or levetiracetam (30-50 mg/kg IV at 100 mg/min)—rather than simply increasing the phenytoin dose. 1

Initial Assessment and Immediate Management

Check Phenytoin Level First

• Obtain a stat phenytoin level to determine if the breakthrough seizure is due to subtherapeutic dosing, therapeutic failure, or paradoxically, phenytoin toxicity 2, 3
• Therapeutic range is 10-20 mcg/mL, though some patients may require higher levels for seizure control 4, 3
• Critical caveat: Phenytoin can paradoxically cause seizures at both subtherapeutic AND supratherapeutic levels 5, 2

Rule Out Reversible Causes

• Evaluate for hypoglycemia, hyponatremia, hypoxia, drug toxicity, CNS infection, or withdrawal syndromes 1
• These conditions require specific treatment in addition to seizure management 1

Second-Line Agent Selection

The Neurocritical Care Society and European Federation of Neurological Societies recommend adding valproate, levetiracetam, or phenobarbital when phenytoin fails 1

Valproate (Preferred Option)

• Dose: 20-30 mg/kg IV at 40 mg/min 1
• Efficacy: 79% seizure control as second-line agent after phenytoin failure (vs. only 25% with additional phenytoin) 1
• Advantages: Can be given more quickly than phenytoin with fewer adverse effects, no hypotension risk 1
• Adverse effects: Dizziness, thrombocytopenia, liver toxicity, hyperammonemia 1

Levetiracetam (Alternative Option)

• Dose: 30-50 mg/kg IV at 100 mg/min 1
• Efficacy: 68-73% seizure cessation when used after phenytoin failure 1
• Advantages: Minimal hypotension or respiratory depression risk, safer adverse effect profile 1
• Adverse effects: Nausea, rash (minimal) 1

Recent High-Quality Evidence (ESETT Trial)

The 2024 ESETT trial (Class I evidence) demonstrated that levetiracetam, fosphenytoin, and valproate have equivalent efficacy (~45-47% success) for benzodiazepine-refractory status epilepticus, with no significant differences in safety outcomes 1. This supports using any of these three agents when phenytoin monotherapy fails.

For Refractory Status Epilepticus

If seizures continue despite second-line agents:

Third-Line Options

• Propofol: 2 mg/kg bolus, then 5 mg/kg/hr infusion (requires intubation) 1
• Phenobarbital: 10-20 mg/kg, may repeat 5-10 mg/kg at 10 minutes 1
• Midazolam: Anesthetic doses per European Federation guidelines 1

Important: Propofol requires fewer ventilator days than pentobarbital (4 vs. 14 days) but requires hemodynamic stability 1

Critical Pitfalls to Avoid

Do Not Simply Increase Phenytoin Dose

• The Veterans Affairs cooperative study showed only 56% success with phenytoin even at therapeutic levels 1
• Supratherapeutic phenytoin levels can paradoxically cause seizures 5, 2
• Phenytoin has significant adverse effects: hypotension, cardiac dysrhythmias, purple glove syndrome 1

Monitor for Phenytoin Toxicity

• Toxic levels can cause confusional states, encephalopathy, or irreversible cerebellar dysfunction 4
• In one study, 87.5% of patients with breakthrough seizures on phenytoin had therapeutic levels at the time of seizure, suggesting therapeutic failure rather than inadequate dosing 6

Avoid Abrupt Phenytoin Withdrawal

• Abrupt discontinuation can precipitate status epilepticus 4
• If switching agents due to allergy/hypersensitivity, rapid substitution with a non-hydantoin alternative is necessary 4

Dosing Considerations

• Phenytoin has nonlinear (Michaelis-Menten) kinetics: Small dose increases can cause disproportionate level increases 4
• Allow 7-10 days to reach steady state before making dosage adjustments 4
• In patients with hepatic impairment or elderly patients, phenytoin metabolism may be impaired, increasing toxicity risk 4

Long-Term Management

For patients with recurrent breakthrough seizures on phenytoin, consider transitioning to an alternative maintenance regimen rather than continuing to escalate phenytoin, given its narrow therapeutic window and significant adverse effect profile 4, 7.